{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:51:18Z","timestamp":1768834278883,"version":"3.49.0"},"reference-count":157,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors (PCSK9-I) are novel therapeutic tools to decrease cardiovascular risk. These agents work by lowering the low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients who are statin resistant\/intolerant. Current clinically approved and investigational PCSK9- I act generally by blocking PCSK9 activity in the plasma or suppressing its expression or secretion by hepatocytes. The most widely investigated method is the disruption of PCSK9\/LDL receptor (LDLR) interaction by fully-humanized monoclonal antibodies (mAbs), evolocumab and alirocumab, which have been approved for the therapy of hypercholesterolemia and atherosclerotic cardiovascular disease (CVD). Besides, a small interfering RNA called inclisiran, which specifically suppresses PCSK9 expression in hepatocytes, is as effective as mAbs but with administration twice a year. Because of the high costs of such therapeutic approaches, several other PCSK9-I have been surveyed, including peptide-based anti-PCSK9 vaccines and small oral anti-PCSK9 molecules, which are under investigation in preclinical and phase I clinical studies. Interestingly, anti-PCSK9 vaccination has been found to serve as a more widely feasible and more cost-effective therapeutic tool over mAb PCSK9-I for managing hypercholesterolemia. The present review will discuss LDL-lowering and cardioprotective effects of PCSK9-I, mainly immunotherapy- based inhibitors including mAbs and vaccines, in preclinical and clinical studies.<\/jats:p><\/jats:sec>","DOI":"10.2174\/0929867328666211027125245","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T07:42:58Z","timestamp":1635493378000},"page":"980-999","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective"],"prefix":"10.2174","volume":"29","author":[{"given":"Amir Abbas","family":"Momtazi-Borojeni","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[{"name":"Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, 06129, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran | Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran | School of Medicine, The University of Western Australia, Perth, Australia | School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017,376(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"Schwartz G.G.","year":"2018","unstructured":"Schwartz G.G.; Steg P.G.; Szarek M.; Bhatt D.L.; Bittner V.A.; Diaz R.; Edelberg J.M.; Goodman S.G.; Hanotin C.; Harrington R.A.; Jukema J.W.; Lecorps G.; Mahaffey K.W.; Moryusef A.; Pordy R.; Quintero K.; Roe M.T.; Sasiela W.J.; Tamby J.F.; Tricoci P.; White H.D.; Zeiher A.M.; Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018,379(22),2097-2107","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.5114\/aoms.2020.94655","volume":"16","author":"Reiner \u017d.","year":"2020","unstructured":"Reiner \u017d.; Hatamipour M.; Banach M.; Pirro M.; Al-Rasadi K.; Jamialahmadi T.; Radenkovic D.; Montecucco F.; Sahebkar A.; Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch Med Sci 2020,16(3),490-496","journal-title":"Arch Med Sci"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1160\/TH14-11-0937","volume":"114","author":"Sahebkar A.","year":"2015","unstructured":"Sahebkar A.; Serban C.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Muntner P.; Bittner V.; Ray K.K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.; Banach M.; Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost Available from: 2015,114(3),546-557","journal-title":"Thromb Haemost"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1160\/th15-08-0620","volume":"115","author":"Sahebkar A.","year":"2016","unstructured":"Sahebkar A.; Serban C.; Ursoniu S.; Mikhailidis D.P.; Undas A.; Lip G.Y.H.; Bittner V.; Ray K.; Watts G.F.; Hovingh G.K.; Rysz J.; Kastelein J.J.; Banach M.; The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost 2016,115(3),520-532","journal-title":"Thromb Haemost"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1038\/srep09902","volume":"5","author":"Serban C.","year":"2015","unstructured":"Serban C.; Sahebkar A.; Ursoniu S.; Mikhailidis D.P.; Rizzo M.; Lip G.Y.H.; Kees Hovingh G.; Kastelein J.J.; Kalinowski L.; Rysz J.; Banach M.; A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep 2015,5,9902","journal-title":"Sci Rep"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.arr.2020.101024","volume":"58","author":"Bahrami A.","year":"2020","unstructured":"Bahrami A.; Bo S.; Jamialahmadi T.; Sahebkar A.; Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev 2020,58,101024","journal-title":"Ageing Res Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jcsm.12654","volume":"12","author":"Mollazadeh H.","year":"2021","unstructured":"Mollazadeh H.; Tavana E.; Fanni G.; Bo S.; Banach M.; Pirro M.; von Haehling S.; Jamialahmadi T.; Sahebkar A.; Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle 2021,12(2),237-251","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","volume":"60","author":"Ferretti G.","year":"2015","unstructured":"Ferretti G.; Bacchetti T.; Sahebkar A.; Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res 2015,60,50-73","journal-title":"Prog Lipid Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","volume":"35","author":"Sahebkar A.","year":"2013","unstructured":"Sahebkar A.; Watts G.F.; New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther 2013,35(8),1082-1098","journal-title":"Clin Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.hjc.2019.10.003","volume":"61","author":"Rallidis L.S.","year":"2020","unstructured":"Rallidis L.S.; Skoumas I.; Liberopoulos E.N.; Vlachopoulos C.; Kiouri E.; Koutagiar I.; Anastasiou G.; Kosmas N.; Elisaf M.S.; Tousoulis D.; Iliodromitis E.; PCSK9 inhibitors in clinical practice: Novel directions and new experiences. Hellenic J Cardiol 2020,61(4),241-245","journal-title":"Hellenic J Cardiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","volume":"27","author":"Sahebkar A.","year":"2013","unstructured":"Sahebkar A.; Watts G.F.; New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther 2013,27(6),559-567","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","volume":"72","author":"Banach M.","year":"2018","unstructured":"Banach M.; Patti A.M.; Giglio R.V.; Cicero A.F.G.; Atanasov A.G.; Bajraktari G.; Bruckert E.; Descamps O.; Djuric D.M.; Ezhov M.; Fras Z.; von Haehling S.; Katsiki N.; Langlois M.; Latkovskis G.; Mancini G.B.J.; Mikhailidis D.P.; Mitchenko O.; Moriarty P.M.; Muntner P.; Nikolic D.; Panagiotakos D.B.; Paragh G.; Paulweber B.; Pella D.; Pitsavos C.; Reiner \u017d.; Rosano G.M.C.; Rosenson R.S.; Rysz J.; Sahebkar A.; Serban M.C.; Vinereanu D.; Vrabl\u00edk M.; Watts G.F.; Wong N.D.; Rizzo M.; The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol 2018,72(1),96-118","journal-title":"J Am Coll Cardiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","volume":"48","author":"Qian Y-W.","year":"2007","unstructured":"Qian Y-W.; Schmidt R.J.; Zhang Y.; Chu S.; Lin A.; Wang H.; Wang X.; Beyer T.P.; Bensch W.R.; Li W.; Ehsani M.E.; Lu D.; Konrad R.J.; Eacho P.I.; Moller D.E.; Karathanasis S.K.; Cao G.; Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007,48(7),1488-1498","journal-title":"J Lipid Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/326760a0","volume":"326","author":"Davis C.G.","year":"1987","unstructured":"Davis C.G.; Goldstein J.L.; S\u00fcdhof T.C.; Anderson R.G.; Russell D.W.; Brown M.S.; Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region. Nature 1987,326(6115),760-765","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1126\/science.1078124","volume":"298","author":"Rudenko G.","year":"2002","unstructured":"Rudenko G.; Henry L.; Henderson K.; Ichtchenko K.; Brown M.S.; Goldstein J.L.; Deisenhofer J.; Structure of the LDL receptor extracellular domain at endosomal pH. Science 2002,298(5602),2353-2358","journal-title":"Science"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1042\/bj2770677","volume":"277","author":"van der Westhuyzen D.R.","year":"1991","unstructured":"van der Westhuyzen D.R.; Stein M.L.; Henderson H.E.; Marais A.D.; Fourie A.M.; Coetzee G.A.; Deletion of two growth-factor repeats from the low-density-lipoprotein receptor accelerates its degradation. Biochem J 1991,277(Pt 3),677-682","journal-title":"Biochem J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"Zhang D-W.","year":"2007","unstructured":"Zhang D-W.; Lagace T.A.; Garuti R.; Zhao Z.; McDonald M.; Horton J.D.; Cohen J.C.; Hobbs H.H.; Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007,282(25),18602-18612","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1073\/pnas.0712064105","volume":"105","author":"Kwon H.J.","year":"2008","unstructured":"Kwon H.J.; Lagace T.A.; McNutt M.C.; Horton J.D.; Deisenhofer J.; Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008,105(6),1820-1825","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"Abifadel M.","year":"2003","unstructured":"Abifadel M.; Varret M.; Rab\u00e8s J-P.; Allard D.; Ouguerram K.; Devillers M.; Cruaud C.; Benjannet S.; Wickham L.; Erlich D.; Derr\u00e9 A.; Vill\u00e9ger L.; Farnier M.; Beucler I.; Bruckert E.; Chambaz J.; Chanu B.; Lecerf J.M.; Luc G.; Moulin P.; Weissenbach J.; Prat A.; Krempf M.; Junien C.; Seidah N.G.; Boileau C.; Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003,34(2),154-156","journal-title":"Nat Genet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"Cohen J.","year":"2005","unstructured":"Cohen J.; Pertsemlidis A.; Kotowski I.K.; Graham R.; Garcia C.K.; Hobbs H.H.; Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005,37(2),161-165","journal-title":"Nat Genet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"Cohen J.C.","year":"2006","unstructured":"Cohen J.C.; Boerwinkle E.; Mosley T.H.; Hobbs H.H.; Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006,354(12),1264-1272","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Zhao Z.","year":"2006","unstructured":"Zhao Z.; Tuakli-Wosornu Y.; Lagace T.A.; Kinch L.; Grishin N.V.; Horton J.D.; Cohen J.C.; Hobbs H.H.; Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006,79(3),514-523","journal-title":"Am J Hum Genet"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"Hooper A.J.","year":"2007","unstructured":"Hooper A.J.; Marais A.D.; Tanyanyiwa D.M.; Burnett J.R.; The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007,193(2),445-448","journal-title":"Atherosclerosis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"Horton J.D.","year":"2009","unstructured":"Horton J.D.; Cohen J.C.; Hobbs H.H.; PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res 2009,50(Suppl.),S172-S177","journal-title":"J Lipid Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1210\/jc.2009-0141","volume":"94","author":"Lakoski S.G.","year":"2009","unstructured":"Lakoski S.G.; Lagace T.A.; Cohen J.C.; Horton J.D.; Hobbs H.H.; Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009,94(7),2537-2543","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","volume":"58","author":"Awan Z.","year":"2012","unstructured":"Awan Z.; Seidah N.G.; MacFadyen J.G.; Benjannet S.; Chasman D.I.; Ridker P.M.; Genest J.; Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012,58(1),183-189","journal-title":"Clin Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"Dubuc G.","year":"2004","unstructured":"Dubuc G.; Chamberland A.; Wassef H.; Davignon J.; Seidah N.G.; Bernier L.; Prat A.; Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004,24(8),1454-1459","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"Poirier S.","year":"2008","unstructured":"Poirier S.; Mayer G.; Benjannet S.; Bergeron E.; Marcinkiewicz J.; Nassoury N.; Mayer H.; Nimpf J.; Prat A.; Seidah N.G.; The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008,283(4),2363-2372","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","volume":"31","author":"Roubtsova A.","year":"2011","unstructured":"Roubtsova A.; Munkonda M.N.; Awan Z.; Marcinkiewicz J.; Chamberland A.; Lazure C.; Cianflone K.; Seidah N.G.; Prat A.; Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011,31(4),785-791","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/cvr\/cvw053","volume":"110","author":"Tavori H.","year":"2016","unstructured":"Tavori H.; Giunzioni I.; Predazzi I.M.; Plubell D.; Shivinsky A.; Miles J.; Devay R.M.; Liang H.; Rashid S.; Linton M.F.; Fazio S.; Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res 2016,110(2),268-278","journal-title":"Cardiovasc Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"Canuel M.","year":"2013","unstructured":"Canuel M.; Sun X.; Asselin M-C.; Paramithiotis E.; Prat A.; Seidah N.G.; Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS One 2013,8(5),e64145","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","volume":"35","author":"Demers A.","year":"2015","unstructured":"Demers A.; Samami S.; Lauzier B.; Des Rosiers C.; Ngo Sock E.T.; Ong H.; Mayer G.; PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol 2015,35(12),2517-2525","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11789-017-0085-0","volume":"12","author":"Schulz R.","year":"2017","unstructured":"Schulz R.; Schl\u00fcter K-D.; PCSK9 targets important for lipid metabolism. Clin Res Cardiol Suppl 2017,12(Suppl. 1),2-11","journal-title":"Clin Res Cardiol Suppl"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/MOL.0000000000000180","volume":"26","author":"Cariou B.","year":"2015","unstructured":"Cariou B.; Si-Tayeb K.; Le May C.; Role of PCSK9 beyond liver involvement. Curr Opin Lipidol 2015,26(3),155-161","journal-title":"Curr Opin Lipidol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"Zaid A.","year":"2008","unstructured":"Zaid A.; Roubtsova A.; Essalmani R.; Marcinkiewicz J.; Chamberland A.; Hamelin J.; Tremblay M.; Jacques H.; Jin W.; Davignon J.; Seidah N.G.; Prat A.; Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008,48(2),646-654","journal-title":"Hepatology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","volume":"40","author":"Da Dalt L.","year":"2019","unstructured":"Da Dalt L.; Ruscica M.; Bonacina F.; Balzarotti G.; Dhyani A.; Di Cairano E.; Baragetti A.; Arnaboldi L.; De Metrio S.; Pellegatta F.; Grigore L.; Botta M.; Macchi C.; Uboldi P.; Perego C.; Catapano A.L.; Norata G.D.; PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. Eur Heart J 2019,40(4),357-368","journal-title":"Eur Heart J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.bbrc.2009.10.138","volume":"390","author":"Langhi C.","year":"2009","unstructured":"Langhi C.; Le May C.; Gmyr V.; Vandewalle B.; Kerr-Conte J.; Krempf M.; Pattou F.; Costet P.; Cariou B.; PCSK9 is expressed in pancreatic \u03b4-cells and does not alter insulin secretion. Biochem Biophys Res Commun 2009,390(4),1288-1293","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","volume":"69","author":"Kysenius K.","year":"2012","unstructured":"Kysenius K.; Muggalla P.; M\u00e4tlik K.; Arum\u00e4e U.; Huttunen H.J.; PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci 2012,69(11),1903-1916","journal-title":"Cell Mol Life Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2008.132","volume":"9","author":"Jonas M.C.","year":"2008","unstructured":"Jonas M.C.; Costantini C.; Puglielli L.; PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep 2008,9(9),916-922","journal-title":"EMBO Rep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/13543776.2016.1206080","volume":"26","author":"Elbitar S.","year":"2016","unstructured":"Elbitar S.; Khoury P.E.; Ghaleb Y.; Rab\u00e8s J-P.; Varret M.; Seidah N.G.; Boileau C.; Abifadel M.; Proprotein convertase subtilisin \/ kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: An updated patent review (2011-2015). Expert Opin Ther Pat 2016,26(12),1377-1392","journal-title":"Expert Opin Ther Pat"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3389\/fcvm.2018.00199","volume":"5","author":"Nishikido T.","year":"2019","unstructured":"Nishikido T.; Ray K.K.; Non-antibody Approaches to proprotein convertase Subtilisin Kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries. Front Cardiovasc Med 2019,5,199","journal-title":"Front Cardiovasc Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11883-020-00847-7","volume":"22","author":"Catapano A.L.","year":"2020","unstructured":"Catapano A.L.; Pirillo A.; Norata G.D.; New pharmacological approaches to target PCSK9. Curr Atheroscler Rep 2020,22(7),24","journal-title":"Curr Atheroscler Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","volume":"290","author":"Dong B.","year":"2015","unstructured":"Dong B.; Li H.; Singh A.B.; Cao A.; Liu J.; Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1\u03b1 protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem 2015,290(7),4047-4058","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"102650","DOI":"10.1016\/j.ebiom.2020.102650","volume":"52","author":"Wang X.","year":"2020","unstructured":"Wang X.; Chen X.; Zhang X.; Su C.; Yang M.; He W.; Du Y.; Si S.; Wang L.; Hong B.; A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1\/3 and HNF1\u03b1. EBioMedicine 2020,52,102650","journal-title":"EBioMedicine"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"ehab299","DOI":"10.1093\/eurheartj\/ehab299","author":"Sahebkar A.","year":"2021","unstructured":"Sahebkar A.; Momtazi-Borojeni A.A.; Banach M.; PCSK9 vaccine: So near, yet so far! Eur Heart J 2021,ehab299","journal-title":"Eur Heart J"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"595819","DOI":"10.3389\/fphys.2020.595819","volume":"11","author":"Katzmann J.L.","year":"2020","unstructured":"Katzmann J.L.; Gouni-Berthold I.; Laufs U.; PCSK9 inhibition: Insights from clinical trials and future prospects. Front Physiol 2020,11,595819","journal-title":"Front Physiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"Ridker P.M.","year":"2017","unstructured":"Ridker P.M.; Tardif J-C.; Amarenco P.; Duggan W.; Glynn R.J.; Jukema J.W.; Kastelein J.J.P.; Kim A.M.; Koenig W.; Nissen S.; Revkin J.; Rose L.M.; Santos R.D.; Schwartz P.F.; Shear C.L.; Yunis C.; Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med 2017,376(16),1517-1526","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"Sabatine M.S.","year":"2015","unstructured":"Sabatine M.S.; Giugliano R.P.; Wiviott S.D.; Raal F.J.; Blom D.J.; Robinson J.; Ballantyne C.M.; Somaratne R.; Legg J.; Wasserman S.M.; Scott R.; Koren M.J.; Stein E.A.; Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015,372(16),1500-1509","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"Robinson J.G.","year":"2015","unstructured":"Robinson J.G.; Farnier M.; Krempf M.; Bergeron J.; Luc G.; Averna M.; Stroes E.S.; Langslet G.; Raal F.J.; El Shahawy M.; Koren M.J.; Lepor N.E.; Lorenzato C.; Pordy R.; Chaudhari U.; Kastelein J.J.; Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015,372(16),1489-1499","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e006910","DOI":"10.1161\/JAHA.117.006910","volume":"6","author":"Karatasakis A.","year":"2017","unstructured":"Karatasakis A.; Danek B.A.; Karacsonyi J.; Rangan B.V.; Roesle M.K.; Knickelbine T.; Miedema M.D.; Khalili H.; Ahmad Z.; Abdullah S.; Banerjee S.; Brilakis E.S.; Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A meta-analysis of 35 randomized controlled trials. J Am Heart Assoc 2017,6(12),e006910","journal-title":"J Am Heart Assoc"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1177\/1060028015608487","volume":"49","author":"White C.M.","year":"2015","unstructured":"White C.M.; Therapeutic potential and critical analysis of the PCSK9 monoclonal antibodies evolocumab and alirocumab. Ann Pharmacother 2015,49(12),1327-1335","journal-title":"Ann Pharmacother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","volume":"254","author":"Roth E.M.","year":"2016","unstructured":"Roth E.M.; Moriarty P.M.; Bergeron J.; Langslet G.; Manvelian G.; Zhao J.; Baccara-Dinet M.T.; Rader D.J.; A phase III randomized trial evaluating alirocumab 300mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis 2016,254,254-262","journal-title":"Atherosclerosis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/jcph.866","volume":"57","author":"Scherer N.","year":"2017","unstructured":"Scherer N.; Dings C.; B\u00f6hm M.; Laufs U.; Lehr T.; Alternative treatment regimens with the PCSK9 inhibitors alirocumab and evolocumab: A pharmacokinetic and pharmacodynamic modeling approach. J Clin Pharmacol 2017,57(7),846-854","journal-title":"J Clin Pharmacol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","volume":"76","author":"Blom D.J.","year":"2020","unstructured":"Blom D.J.; Harada-Shiba M.; Rubba P.; Gaudet D.; Kastelein J.J.P.; Charng M-J.; Pordy R.; Donahue S.; Ali S.; Dong Y.; Khilla N.; Banerjee P.; Baccara-Dinet M.; Rosenson R.S.; Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH trial. J Am Coll Cardiol 2020,76(2),131-142","journal-title":"J Am Coll Cardiol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17425255.2020.1828343","volume":"16","author":"Mo\u015fteoru S.","year":"2020","unstructured":"Mo\u015fteoru S.; Gai\u0163\u0103 D.; Banach M.; An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity. Expert Opin Drug Metab Toxicol 2020,16(12),1199-1205","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"Koren M.J.","year":"2014","unstructured":"Koren M.J.; Lundqvist P.; Bolognese M.; Neutel J.M.; Monsalvo M.L.; Yang J.; Kim J.B.; Scott R.; Wasserman S.M.; Bays H.; Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014,63(23),2531-2540","journal-title":"J Am Coll Cardiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"Robinson J.G.","year":"2014","unstructured":"Robinson J.G.; Nedergaard B.S.; Rogers W.J.; Fialkow J.; Neutel J.M.; Ramstad D.; Somaratne R.; Legg J.C.; Nelson P.; Scott R.; Wasserman S.M.; Weiss R.; Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014,311(18),1870-1882","journal-title":"JAMA"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"Blom D.J.","year":"2014","unstructured":"Blom D.J.; Hala T.; Bolognese M.; Lillestol M.J.; Toth P.D.; Burgess L.; Ceska R.; Roth E.; Koren M.J.; Ballantyne C.M.; Monsalvo M.L.; Tsirtsonis K.; Kim J.B.; Scott R.; Wasserman S.M.; Stein E.A.; A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014,370(19),1809-1819","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"Nicholls S.J.","year":"2016","unstructured":"Nicholls S.J.; Puri R.; Anderson T.; Ballantyne C.M.; Cho L.; Kastelein J.J.; Koenig W.; Somaratne R.; Kassahun H.; Yang J.; Wasserman S.M.; Scott R.; Ungi I.; Podolec J.; Ophuis A.O.; Cornel J.H.; Borgman M.; Brennan D.M.; Nissen S.E.; Effect of evolocumab on progression of coronary disease in statin-treated patients: The glagov randomized clinical trial. JAMA 2016,316(22),2373-2384","journal-title":"JAMA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"Koskinas K.C.","year":"2019","unstructured":"Koskinas K.C.; Windecker S.; Pedrazzini G.; Mueller C.; Cook S.; Matter C.M.; Muller O.; H\u00e4ner J.; Gencer B.; Crljenica C.; Amini P.; Deckarm O.; Iglesias J.F.; R\u00e4ber L.; Heg D.; Mach F.; Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol 2019,74(20),2452-2462","journal-title":"J Am Coll Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"Stroes E.","year":"2014","unstructured":"Stroes E.; Colquhoun D.; Sullivan D.; Civeira F.; Rosenson R.S.; Watts G.F.; Bruckert E.; Cho L.; Dent R.; Knusel B.; Xue A.; Scott R.; Wasserman S.M.; Rocco M.; Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 2014,63(23),2541-2548","journal-title":"J Am Coll Cardiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"Nissen S.E.","year":"2016","unstructured":"Nissen S.E.; Stroes E.; Dent-Acosta R.E.; Rosenson R.S.; Lehman S.J.; Sattar N.; Preiss D.; Bruckert E.; Ce\u0161ka R.; Lepor N.; Ballantyne C.M.; Gouni-Berthold I.; Elliott M.; Brennan D.M.; Wasserman S.M.; Somaratne R.; Scott R.; Stein E.A.; Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 2016,315(15),1580-1590","journal-title":"JAMA"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","volume":"12","author":"Mannarino M.R.","year":"2018","unstructured":"Mannarino M.R.; Sahebkar A.; Bianconi V.; Serban M.C.; Banach M.; Pirro M.; PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J Clin Lipidol 2018,12(5),1123-1132","journal-title":"J Clin Lipidol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","volume":"74","author":"Koren M.J.","year":"2019","unstructured":"Koren M.J.; Sabatine M.S.; Giugliano R.P.; Langslet G.; Wiviott S.D.; Ruzza A.; Ma Y.; Hamer A.W.; Wasserman S.M.; Raal F.J.; Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol 2019,74(17),2132-2146","journal-title":"J Am Coll Cardiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Stein E.A.; Dufour R.; Turner T.; Civeira F.; Burgess L.; Langslet G.; Scott R.; Olsson A.G.; Sullivan D.; Hovingh G.K.; Cariou B.; Gouni-Berthold I.; Somaratne R.; Bridges I.; Scott R.; Wasserman S.M.; Gaudet D.; PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial. Lancet 2015,385(9965),331-340","journal-title":"Lancet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","volume":"383","author":"Santos R.D.","year":"2020","unstructured":"Santos R.D.; Ruzza A.; Hovingh G.K.; Wiegman A.; Mach F.; Kurtz C.E.; Hamer A.; Bridges I.; Bartuli A.; Bergeron J.; Szamosi T.; Santra S.; Stefanutti C.; Descamps O.S.; Greber-Platzer S.; Luirink I.; Kastelein J.J.P.; Gaudet D.; Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med 2020,383(14),1317-1327","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"Raal F.J.","year":"2015","unstructured":"Raal F.J.; Honarpour N.; Blom D.J.; Hovingh G.K.; Xu F.; Scott R.; Wasserman S.M.; Stein E.A.; Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial. Lancet 2015,385(9965),341-350","journal-title":"Lancet"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","volume":"5","author":"Raal F.J.","year":"2017","unstructured":"Raal F.J.; Hovingh G.K.; Blom D.; Santos R.D.; Harada-Shiba M.; Bruckert E.; Couture P.; Soran H.; Watts G.F.; Kurtz C.; Honarpour N.; Tang L.; Kasichayanula S.; Wasserman S.M.; Stein E.A.; Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: An interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017,5(4),280-290","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","volume":"75","author":"Santos R.D.","year":"2020","unstructured":"Santos R.D.; Stein E.A.; Hovingh G.K.; Blom D.J.; Soran H.; Watts G.F.; L\u00f3pez J.A.G.; Bray S.; Kurtz C.E.; Hamer A.W.; Raal F.J.; Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol 2020,75(6),565-574","journal-title":"J Am Coll Cardiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","volume":"176","author":"Roth E.M.","year":"2014","unstructured":"Roth E.M.; Taskinen M-R.; Ginsberg H.N.; Kastelein J.J.; Colhoun H.M.; Robinson J.G.; Merlet L.; Pordy R.; Baccara-Dinet M.T.; Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014,176(1),55-61","journal-title":"Int J Cardiol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"Kereiakes D.J.","year":"2015","unstructured":"Kereiakes D.J.; Robinson J.G.; Cannon C.P.; Lorenzato C.; Pordy R.; Chaudhari U.; Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J 2015,169(6),906-915","journal-title":"Am Heart J"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1111\/dom.13114","volume":"19","author":"Leiter L.A.","year":"2017","unstructured":"Leiter L.A.; Cariou B.; M\u00fcller-Wieland D.; Colhoun H.M.; Del Prato S.; Tinahones F.J.; Ray K.K.; Bujas-Bobanovic M.; Domenger C.; Mandel J.; Samuel R.; Henry R.R.; Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 2017,19(12),1781-1792","journal-title":"Diabetes Obes Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"Moriarty P.M.","year":"2015","unstructured":"Moriarty P.M.; Thompson P.D.; Cannon C.P.; Guyton J.R.; Bergeron J.; Zieve F.J.; Bruckert E.; Jacobson T.A.; Kopecky S.L.; Baccara-Dinet M.T.; Du Y.; Pordy R.; Gipe D.A.; Efficacy and safety of alirocumab vs. ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 2015,9(6),758-769","journal-title":"J Clin Lipidol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1093\/eurheartj\/ehv370","volume":"36","author":"Kastelein J.J.","year":"2015","unstructured":"Kastelein J.J.; Ginsberg H.N.; Langslet G.; Hovingh G.K.; Ceska R.; Dufour R.; Blom D.; Civeira F.; Krempf M.; Lorenzato C.; Zhao J.; Pordy R.; Baccara-Dinet M.T.; Gipe D.A.; Geiger M.J.; Farnier M.; ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015,36(43),2996-3003","journal-title":"Eur Heart J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/17512433.2020.1787832","volume":"13","author":"van Bruggen F.H.","year":"2020","unstructured":"van Bruggen F.H.; Nijhuis G.B.J.; Zuidema S.U.; Luijendijk H.; Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review. Expert Rev Clin Pharmacol 2020,13(7),787-796","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"Grundy S.M.","year":"2019","unstructured":"Grundy S.M.; Stone N.J.; Bailey A.L.; Beam C.; Birtcher K.K.; Blumenthal R.S.; Braun L.T.; de Ferranti S.; Faiella-Tommasino J.; Forman D.E.; Goldberg R.; Heidenreich P.A.; Hlatky M.A.; Jones D.W.; Lloyd-Jones D.; Lopez-Pajares N.; Ndumele C.E.; Orringer C.E.; Peralta C.A.; Saseen J.J.; Smith S.C.; Sperling L.; Virani S.S.; Yeboah J.; 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association TaskForceonClinical Practice Guidelines. J Am Coll Cardiol 2019,73(24),e285-e350","journal-title":"J Am Coll Cardiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"Mach F.","year":"2020","unstructured":"Mach F.; Baigent C.; Catapano A.L.; Koskinas K.C.; Casula M.; Badimon L.; Chapman M.J.; De Backer G.G.; Delgado V.; Ference B.A.; Graham I.M.; Halliday A.; Landmesser U.; Mihaylova B.; Pedersen T.R.; Riccardi G.; Richter D.J.; Sabatine M.S.; Taskinen M.R.; Tokgozoglu L.; Wiklund O.; 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020,41(1),111-188","journal-title":"Eur Heart J"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"Kazi D.S.","year":"2016","unstructured":"Kazi D.S.; Moran A.E.; Coxson P.G.; Penko J.; Ollendorf D.A.; Pearson S.D.; Tice J.A.; Guzman D.; Bibbins-Domingo K.; Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 2016,316(7),743-753","journal-title":"JAMA"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/M18-1776","volume":"170","author":"Kazi D.S.","year":"2019","unstructured":"Kazi D.S.; Penko J.; Coxson P.G.; Guzman D.; Wei P.C.; Bibbins-Domingo K.; Cost-effectiveness of alirocumab: A just-in-time analysis based on the ODYSSEY outcomes trial. Ann Intern Med 2019,170(4),221-229","journal-title":"Ann Intern Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","volume":"318","author":"Kazi D.S.","year":"2017","unstructured":"Kazi D.S.; Penko J.; Coxson P.G.; Moran A.E.; Ollendorf D.A.; Tice J.A.; Bibbins-Domingo K.; Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 2017,318(8),748-750","journal-title":"JAMA"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"E162","DOI":"10.9778\/cmajo.20180011","volume":"6","author":"Lee T.C.","year":"2018","unstructured":"Lee T.C.; Kaouache M.; Grover S.A.; Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: A Canadian analysis. CMAJ Open 2018,6(2),E162-E167","journal-title":"CMAJ Open"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"e001018","DOI":"10.1136\/openhrt-2019-001018","volume":"6","author":"Brunetti N.D.","year":"2019","unstructured":"Brunetti N.D.; De Gennaro L.; Tricarico L.; Caldarola P.; Budget impact analysis of PCSK9 inhibitors costs from a community payers\u2019 perspective in Apulia, Italy. Open Heart 2019,6(2),e001018","journal-title":"Open Heart"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"106566","DOI":"10.1016\/j.vph.2019.106566","volume":"120","author":"Dressel A.","year":"2019","unstructured":"Dressel A.; Schmidt B.; Schmidt N.; Laufs U.; Fath F.; Chapman M.J.; Grammer T.B.; M\u00e4rz W.; Cost effectiveness of lifelong therapy with PCSK9 inhibitors for lowering cardiovascular events in patients with stable coronary artery disease: Insights from the Ludwigshafen Risk and Cardiovascular Health cohort. Vascul Pharmacol 2019,120,106566","journal-title":"Vascul Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.jacc.2020.03.029","volume":"75","author":"Bhatt D.L.","year":"2020","unstructured":"Bhatt D.L.; Briggs A.H.; Reed S.D.; Annemans L.; Szarek M.; Bittner V.A.; Diaz R.; Goodman S.G.; Harrington R.A.; Higuchi K.; Joulain F.; Jukema J.W.; Li Q.H.; Mahaffey K.W.; Sanchez R.J.; Roe M.T.; Lopes R.D.; White H.D.; Zeiher A.M.; Schwartz G.G.; Gabriel Steg P.; Cost-effectiveness of alirocumab in patients with acute coronary syndromes: The ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2020,75(18),2297-2308","journal-title":"J Am Coll Cardiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"Bartelds G.M.","year":"2011","unstructured":"Bartelds G.M.; Krieckaert C.L.; Nurmohamed M.T.; van Schouwenburg P.A.; Lems W.F.; Twisk J.W.; Dijkmans B.A.; Aarden L.; Wolbink G.J.; Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011,305(14),1460-1468","journal-title":"JAMA"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tips.2013.01.010","volume":"34","author":"Norata G.D.","year":"2013","unstructured":"Norata G.D.; Tibolla G.; Catapano A.L.; Gene silencing approaches for the management of dyslipidaemia. Trends Pharmacol Sci 2013,34(4),198-205","journal-title":"Trends Pharmacol Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/path.2993","volume":"226","author":"Watts J.K.","year":"2012","unstructured":"Watts J.K.; Corey D.R.; Silencing disease genes in the laboratory and the clinic. J Pathol 2012,226(2),365-379","journal-title":"J Pathol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"Fitzgerald K.","year":"2017","unstructured":"Fitzgerald K.; White S.; Borodovsky A.; Bettencourt B.R.; Strahs A.; Clausen V.; Wijngaard P.; Horton J.D.; Taubel J.; Brooks A.; Fernando C.; Kauffman R.S.; Kallend D.; Vaishnaw A.; Simon A.; A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 2017,376(1),41-51","journal-title":"N Engl J Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1242\/dev.132209","volume":"143","author":"Peters D.T.","year":"2016","unstructured":"Peters D.T.; Henderson C.A.; Warren C.R.; Friesen M.; Xia F.; Becker C.E.; Musunuru K.; Cowan C.A.; Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells. Development 2016,143(9),1475-1481","journal-title":"Development"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1614154","volume":"376","author":"Khvorova A.","year":"2017","unstructured":"Khvorova A.; Oligonucleotide therapeutics\u2014a new class of cholesterol-lowering drugs. N Engl J Med 2017,376(1),4-7","journal-title":"N Engl J Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"Ray K.K.","year":"2017","unstructured":"Ray K.K.; Landmesser U.; Leiter L.A.; Kallend D.; Dufour R.; Karakas M.; Hall T.; Troquay R.P.; Turner T.; Visseren F.L.; Wijngaard P.; Wright R.S.; Kastelein J.J.; Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017,376(15),1430-1440","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.atherosclerosis.2018.06.911","volume":"275","author":"Ray K.","year":"2018","unstructured":"Ray K.; Stoekenbroek R.M.; Kallend D.; Leiter L.; Landmesser U.; Scott-Wright R.; Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1. Atherosclerosis 2018,275,e9","journal-title":"Atherosclerosis"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"Ray K.K.","year":"2019","unstructured":"Ray K.K.; Stoekenbroek R.M.; Kallend D.; Nishikido T.; Leiter L.A.; Landmesser U.; Wright R.S.; Wijngaard P.L.J.; Kastelein J.J.P.; Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol 2019,4(11),1067-1075","journal-title":"JAMA Cardiol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"Raal F.J.","year":"2020","unstructured":"Raal F.J.; Kallend D.; Ray K.K.; Turner T.; Koenig W.; Wright R.S.; Wijngaard P.L.J.; Curcio D.; Jaros M.J.; Leiter L.A.; Kastelein J.J.P.; Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020,382(16),1520-1530","journal-title":"N Engl J Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.018","volume":"287","author":"Raal F.","year":"2019","unstructured":"Raal F.; Lepor N.; Kallend D.; Stoekenbroek R.; Wijngaard P.; Hovingh G.; Inclisiran durably lowers Ldl-C And Pcsk9 expression in subjects with homozygous familial hypercholesterolaemia: the Orion-2 pilot study. Atherosclerosis 2019,287,e7","journal-title":"Atherosclerosis"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fphys.2018.00953","volume":"9","author":"Laina A.","year":"2018","unstructured":"Laina A.; Gatsiou A.; Georgiopoulos G.; Stamatelopoulos K.; Stellos K.; RNA therapeutics in cardiovascular precision medicine. Front Physiol 2018,9,953","journal-title":"Front Physiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"Frazier K.S.","year":"2015","unstructured":"Frazier K.S.; Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol 2015,43(1),78-89","journal-title":"Toxicol Pathol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","volume":"117","author":"Landmesser U.","year":"2020","unstructured":"Landmesser U.; Haghikia A.; Leiter L.A.; Wright R.S.; Kallend D.; Wijngaard P.; Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers-a pre-specified analysis from ORION-1. Cardiovasc Res 2020,117(1),284-291","journal-title":"Cardiovasc Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/cells9030610","volume":"9","author":"Chandler P.G.","year":"2020","unstructured":"Chandler P.G.; Buckle A.M.; Development and differentiation in monobodies based on the fibronectin type 3 domain. Cells 2020,9(3),610","journal-title":"Cells"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.114.214221","volume":"350","author":"Mitchell T.","year":"2014","unstructured":"Mitchell T.; Chao G.; Sitkoff D.; Lo F.; Monshizadegan H.; Meyers D.; Low S.; Russo K.; DiBella R.; Denhez F.; Gao M.; Myers J.; Duke G.; Witmer M.; Miao B.; Ho S.P.; Khan J.; Parker R.A.; Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 2014,350(2),412-424","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"A1372","DOI":"10.1016\/S0735-1097(14)61372-3","volume":"63","author":"Stein E.A.","year":"2014","unstructured":"Stein E.A.; Kasichayanula S.; Turner T.; Kranz T.; Arumugam U.; Biernat L.; LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: Results of a single ascending dose study. J Am Coll Cardiol 2014,63(12S),A1372","journal-title":"J Am Coll Cardiol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0735-1097(19)32320-4","volume":"73","author":"Stein E.A.","year":"2019","unstructured":"Stein E.A.; Turner T.; Biernat L.; Dimova D.; Zhou R.; Dai M.; Low density lipoprotein cholesterol reduction and safety with Lib003, an anti-proprotein convertase subtilisin\/kexin Type 9 fusion protein: Results of a randomized, double-blind, placebo-controlled, single ascending dose study. J Am Coll Cardiol 2019,73(9_Supplement_1),1714","journal-title":"J Am Coll Cardiol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.atherosclerosis.2019.06.019","volume":"287","author":"Stein E.","year":"2019","unstructured":"Stein E.; Toth P.; Butcher M.; Kereiakes D.; Magnu P.; Bays H.; Safety, tolerability and LDL-C reduction with a novel anti-PCSK9 recombinant fusion protein (LIB003): results of a randomized, double-blind, placebo-controlled, phase 2 study. Atherosclerosis 2019,287,e7","journal-title":"Atherosclerosis"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"Ference B.A.","year":"2017","unstructured":"Ference B.A.; Ginsberg H.N.; Graham I.; Ray K.K.; Packard C.J.; Bruckert E.; Hegele R.A.; Krauss R.M.; Raal F.J.; Schunkert H.; Watts G.F.; Bor\u00e9n J.; Fazio S.; Horton J.D.; Masana L.; Nicholls S.J.; Nordestgaard B.G.; van de Sluis B.; Taskinen M.R.; Tokg\u00f6zoglu L.; Landmesser U.; Laufs U.; Wiklund O.; Stock J.K.; Chapman M.J.; Catapano A.L.; Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017,38(32),2459-2472","journal-title":"Eur Heart J"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"Ference B.A.","year":"2012","unstructured":"Ference B.A.; Yoo W.; Alesh I.; Mahajan N.; Mirowska K.K.; Mewada A.; Kahn J.; Afonso L.; Williams K.A.; Flack J.M.; Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis. J Am Coll Cardiol 2012,60(25),2631-2639","journal-title":"J Am Coll Cardiol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.vph.2015.03.008","volume":"71","author":"Packard C.J.","year":"2015","unstructured":"Packard C.J.; Weintraub W.S.; Laufs U.; New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vascul Pharmacol 2015,71,37-39","journal-title":"Vascul Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"e114469","DOI":"10.1371\/journal.pone.0114469","volume":"9","author":"Galabova G.","year":"2014","unstructured":"Galabova G.; Brunner S.; Winsauer G.; Juno C.; Wanko B.; Mairhofer A.; L\u00fchrs P.; Schneeberger A.; von Bonin A.; Mattner F.; Schmidt W.; Staffler G.; Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One 2014,9(12),e114469","journal-title":"PLoS One"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","volume":"38","author":"Landlinger C.","year":"2017","unstructured":"Landlinger C.; Pouwer M.G.; Juno C.; van der Hoorn J.W.A.; Pieterman E.J.; Jukema J.W.; Staffler G.; Princen H.M.G.; Galabova G.; The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. Eur Heart J 2017,38(32),2499-2507","journal-title":"Eur Heart J"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2019.02.001","volume":"283","author":"Momtazi-Borojeni A.A.","year":"2019","unstructured":"Momtazi-Borojeni A.A.; Jaafari M.R.; Badiee A.; Sahebkar A.; Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis 2019,283,69-78","journal-title":"Atherosclerosis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"Ferrer I.","year":"2004","unstructured":"Ferrer I.; Boada Rovira M.; S\u00e1nchez Guerra M.L.; Rey M.J.; Costa-Juss\u00e1 F.; Neuropathology and pathogenesis of encephalitis following amyloid-\u03b2 immunization in Alzheimer\u2019s disease. Brain Pathol 2004,14(1),11-20","journal-title":"Brain Pathol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1586\/14760584.2016.1159136","volume":"15","author":"Chackerian B.","year":"2016","unstructured":"Chackerian B.; Frietze K.M.; Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Rev Vaccines 2016,15(5),561-563","journal-title":"Expert Rev Vaccines"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1126\/science.8248784","volume":"262","author":"Bachmann M.F.","year":"1993","unstructured":"Bachmann M.F.; Rohrer U.H.; K\u00fcndig T.M.; B\u00fcrki K.; Hengartner H.; Zinkernagel R.M.; The influence of antigen organization on B cell responsiveness. Science 1993,262(5138),1448-1451","journal-title":"Science"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4049\/jimmunol.143.4.1239","volume":"143","author":"Dintzis R.Z.","year":"1989","unstructured":"Dintzis R.Z.; Okajima M.; Middleton M.H.; Greene G.; Dintzis H.M.; The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol 1989,143(4),1239-1244","journal-title":"J Immunol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"5816","DOI":"10.4049\/jimmunol.180.9.5816","volume":"180","author":"Chackerian B.","year":"2008","unstructured":"Chackerian B.; Durfee M.R.; Schiller J.T.; Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 2008,180(9),5816-5825","journal-title":"J Immunol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","volume":"236","author":"Amanna I.J.","year":"2010","unstructured":"Amanna I.J.; Slifka M.K.; Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010,236(1),125-138","journal-title":"Immunol Rev"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1002\/jcp.26361","volume":"233","author":"Zamani P.","year":"2018","unstructured":"Zamani P.; Momtazi-Borojeni A.A.; Nik M.E.; Oskuee R.K.; Sahebkar A.; Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. J Cell Physiol 2018,233(7),5189-5199","journal-title":"J Cell Physiol"},{"key":"ref=118","first-page":"M028340","volume":"2012","author":"Fattori E.","year":"2012","unstructured":"Fattori E.; Cappelletti M.; Surdo P.L.; Calzetta A.; Bendtsen C.; Ni Y.G.; Immunization against Proprotein Convertase Subtilisin-like\/Kexin type 9 (PCSK9) lowers plasma LDL-cholesterol levels in mice. J Lipid Res 2012,2012,M028340","journal-title":"J Lipid Res"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","volume":"13","author":"Schneeberger A.","year":"2009","unstructured":"Schneeberger A.; Mandler M.; Otawa O.; Zauner W.; Mattner F.; Schmidt W.; Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)--from concept to clinical testing. J Nutr Health Aging 2009,13(3),264-267","journal-title":"J Nutr Health Aging"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"12534","DOI":"10.1038\/s41598-017-13069-w","volume":"7","author":"Pan Y.","year":"2017","unstructured":"Pan Y.; Zhou Y.; Wu H.; Chen X.; Hu X.; Zhang H.; Zhou Z.; Qiu Z.; Liao Y.; A therapeutic peptide vaccine against PCSK9. Sci Rep 2017,7(1),12534","journal-title":"Sci Rep"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.1016\/j.vaccine.2015.09.044","volume":"33","author":"Crossey E.","year":"2015","unstructured":"Crossey E.; Amar M.J.A.; Sampson M.; Peabody J.; Schiller J.T.; Chackerian B.; Remaley A.T.; A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 2015,33(43),5747-5755","journal-title":"Vaccine"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrd1284","volume":"3","author":"Bachmann M.F.","year":"2004","unstructured":"Bachmann M.F.; Dyer M.R.; Therapeutic vaccination for chronic diseases: A new class of drugs in sight. Nat Rev Drug Discov 2004,3(1),81-88","journal-title":"Nat Rev Drug Discov"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1128\/JVI.78.8.4037-4047.2004","volume":"78","author":"Chackerian B.","year":"2004","unstructured":"Chackerian B.; Briglio L.; Albert P.S.; Lowy D.R.; Schiller J.T.; Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian\/human immunodeficiency virus. J Virol 2004,78(8),4037-4047","journal-title":"J Virol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1128\/JVI.02447-13","volume":"88","author":"Van Rompay K.K.","year":"2014","unstructured":"Van Rompay K.K.; Hunter Z.; Jayashankar K.; Peabody J.; Montefiori D.; LaBranche C.C.; Keele B.F.; Jensen K.; Abel K.; Chackerian B.; A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol 2014,88(4),2011-2024","journal-title":"J Virol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","volume":"17","author":"Momtazi-Borojeni A.A.","year":"2019","unstructured":"Momtazi-Borojeni A.A.; Jaafari M.R.; Badiee A.; Banach M.; Sahebkar A.; Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med 2019,17(1),223","journal-title":"BMC Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.5114\/aoms\/133885","volume":"17","author":"Momtazi-Borojeni A.A.","year":"2021","unstructured":"Momtazi-Borojeni A.A.; Jaafari M.R.; Afshar M.; Banach M.; Sahebkar A.; PCSK9 immunization using nanoliposomes: Preventive efficacy against hypercholesterolemia and atherosclerosis. Arch Med Sci 2021,17(5),1365-1377","journal-title":"Arch Med Sci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2018.09.030","volume":"278","author":"O\u2019Keeffe L.M.","year":"2018","unstructured":"O\u2019Keeffe L.M.; Simpkin A.J.; Tilling K.; Anderson E.L.; Hughes A.D.; Lawlor D.A.; Fraser A.; Howe L.D.; Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: A prospective cohort study. Atherosclerosis 2018,278,190-196","journal-title":"Atherosclerosis"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/CIRCRESAHA.115.307611","volume":"118","author":"Herrington W.","year":"2016","unstructured":"Herrington W.; Lacey B.; Sherliker P.; Armitage J.; Lewington S.; Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016,118(4),535-546","journal-title":"Circ Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"Libby P.","year":"2019","unstructured":"Libby P.; Buring J.E.; Badimon L.; Hansson G.K.; Deanfield J.; Bittencourt M.S.; Tokg\u00f6zo\u011flu L.; Lewis E.F.; Atherosclerosis. Nat Rev Dis Primers 2019,5(1),56","journal-title":"Nat Rev Dis Primers"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S0022-2275(20)37904-9","volume":"24","author":"Camus M.C.","year":"1983","unstructured":"Camus M.C.; Chapman M.J.; Forgez P.; Laplaud P.M.; Distribution and characterization of the serum lipoproteins and apoproteins in the mouse, Mus musculus. J Lipid Res 1983,24(9),1210-1228","journal-title":"J Lipid Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/FJC.0000000000000522","volume":"70","author":"Johnston T.P.","year":"2017","unstructured":"Johnston T.P.; Korolenko T.A.; Sahebkar A.; P-407-induced mouse model of dose-controlled hyperlipidemia and atherosclerosis: 25 years later. J Cardiovasc Pharmacol 2017,70(5),339-352","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI11849","volume":"108","author":"Chackerian B.","year":"2001","unstructured":"Chackerian B.; Lowy D.R.; Schiller J.T.; Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001,108(3),415-423","journal-title":"J Clin Invest"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HJH.0b013e32800ff5d6","volume":"25","author":"Amb\u00fchl P.M.","year":"2007","unstructured":"Amb\u00fchl P.M.; Tissot A.C.; Fulurija A.; Maurer P.; Nussberger J.; Sabat R.; Nief V.; Schellekens C.; Sladko K.; Roubicek K.; Pfister T.; Rettenbacher M.; Volk H.D.; Wagner F.; M\u00fcller P.; Jennings G.T.; Bachmann M.F.; A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007,25(1),63-72","journal-title":"J Hypertens"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(08)60381-5","volume":"371","author":"Tissot A.C.","year":"2008","unstructured":"Tissot A.C.; Maurer P.; Nussberger J.; Sabat R.; Pfister T.; Ignatenko S.; Volk H.D.; Stocker H.; M\u00fcller P.; Jennings G.T.; Wagner F.; Bachmann M.F.; Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008,371(9615),821-827","journal-title":"Lancet"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4161\/hv.28183","volume":"10","author":"Fettelschoss A.","year":"2014","unstructured":"Fettelschoss A.; Zabel F.; Bachmann M.F.; Vaccination against Alzheimer disease: An update on future strategies. Hum Vaccin Immunother 2014,10(4),847-851","journal-title":"Hum Vaccin Immunother"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/vaccines9070749","volume":"9","author":"Momtazi-Borojeni A.A.","year":"2021","unstructured":"Momtazi-Borojeni A.A.; Jaafari M.R.; Banach M.; Gorabi A.M.; Sahraei H.; Sahebkar A.; Pre-clinical evaluation of the nanoliposomal antiPCSK9 vaccine in healthy non-human primates. Vaccines (Basel) 2021,9(7),749","journal-title":"Vaccines (Basel)"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1152\/ajpendo.00528.2014","volume":"309","author":"Miyosawa K.","year":"2015","unstructured":"Miyosawa K.; Watanabe Y.; Murakami K.; Murakami T.; Shibata H.; Iwashita M.; Yamazaki H.; Yamazaki K.; Ohgiya T.; Shibuya K.; Mizuno K.; Tanabe S.; Singh S.A.; Aikawa M.; New CETP inhibitor K-312 reduces PCSK9 expression: A potential effect on LDL cholesterol metabolism. Am J Physiol Endocrinol Metab 2015,309(2),E177-E190","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"e2001882","DOI":"10.1371\/journal.pbio.2001882","volume":"15","author":"Lintner N.G.","year":"2017","unstructured":"Lintner N.G.; McClure K.F.; Petersen D.; Londregan A.T.; Piotrowski D.W.; Wei L.; Xiao J.; Bolt M.; Loria P.M.; Maguire B.; Geoghegan K.F.; Huang A.; Rolph T.; Liras S.; Doudna J.A.; Dullea R.G.; Cate J.H.; Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain. PLoS Biol 2017,15(3),e2001882","journal-title":"PLoS Biol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm1135","volume":"10","author":"Kong W.","year":"2004","unstructured":"Kong W.; Wei J.; Abidi P.; Lin M.; Inaba S.; Li C.; Wang Y.; Wang Z.; Si S.; Pan H.; Wang S.; Wu J.; Wang Y.; Li Z.; Liu J.; Jiang J.D.; Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004,10(12),1344-1351","journal-title":"Nat Med"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","volume":"201","author":"Cameron J.","year":"2008","unstructured":"Cameron J.; Ranheim T.; Kulseth M.A.; Leren T.P.; Berge K.E.; Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008,201(2),266-273","journal-title":"Atherosclerosis"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/eurheartj\/ehu095","volume":"36","author":"Miranda M.X.","year":"2015","unstructured":"Miranda M.X.; van Tits L.J.; Lohmann C.; Arsiwala T.; Winnik S.; Tailleux A.; Stein S.; Gomes A.P.; Suri V.; Ellis J.L.; Lutz T.A.; Hottiger M.O.; Sinclair D.A.; Auwerx J.; Schoonjans K.; Staels B.; L\u00fcscher T.F.; Matter C.M.; The Sirt1 activator SRT3025 provides atheroprotection in Apoe-\/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur Heart J 2015,36(1),51-59","journal-title":"Eur Heart J"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.18632\/oncotarget.12157","volume":"8","author":"Ye X.","year":"2017","unstructured":"Ye X.; Li M.; Hou T.; Gao T.; Zhu W.G.; Yang Y.; Sirtuins in glucose and lipid metabolism. Oncotarget 2017,8(1),1845-1859","journal-title":"Oncotarget"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.fob.2014.08.003","volume":"4","author":"Mbikay M.","year":"2014","unstructured":"Mbikay M.; Sirois F.; Simoes S.; Mayne J.; Chr\u00e9tien M.; Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin\/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Biol 2014,4,755-762","journal-title":"FEBS Open Biol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","volume":"162","author":"Xu S.","year":"2019","unstructured":"Xu S.; Luo S.; Zhu Z.; Xu J.; Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur J Med Chem 2019,162,212-233","journal-title":"Eur J Med Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","volume":"120","author":"Momtazi A.A.","year":"2017","unstructured":"Momtazi A.A.; Banach M.; Pirro M.; Katsiki N.; Sahebkar A.; Regulation of PCSK9 by nutraceuticals. Pharmacol Res 2017,120,157-169","journal-title":"Pharmacol Res"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"Craik D.J.","year":"2013","unstructured":"Craik D.J.; Fairlie D.P.; Liras S.; Price D.; The future of peptide-based drugs. Chem Biol Drug Des 2013,81(1),136-147","journal-title":"Chem Biol Drug Des"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1124\/jpet.117.246652","volume":"365","author":"Masuda Y.","year":"2018","unstructured":"Masuda Y.; Yamaguchi S.; Suzuki C.; Aburatani T.; Nagano Y.; Miyauchi R.; Suzuki E.; Yamamura N.; Nagatomo K.; Ishihara H.; Okuno K.; Nara F.; Matschiner G.; Hashimoto R.; Takahashi T.; Nishizawa T.; Generation and characterization of a novel small biologic alternative to proprotein convertase Subtilisin\/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, albumin binding domain\u2013fused anticalin protein. J Pharmacol Exp Ther 2018,365(2),368-378","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/B978-0-12-396962-0.00007-0","volume":"503","author":"Gebauer M.","year":"2012","unstructured":"Gebauer M.; Skerra A.; Anticalins small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol 2012,503,157-188","journal-title":"Methods Enzymol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.dmpk.2017.12.001","volume":"33","author":"Baverel P.","year":"2018","unstructured":"Baverel P.; She D.; Piper E.; Ueda S.; Yoshioka T.; Faggioni R.; Gevorkyan H.; A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metab Pharmacokinet 2018,33(3),150-158","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"31791","DOI":"10.1074\/jbc.M805971200","volume":"283","author":"Mayer G.","year":"2008","unstructured":"Mayer G.; Poirier S.; Seidah N.G.; Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 2008,283(46),31791-31801","journal-title":"J Biol Chem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"e41865","DOI":"10.1371\/journal.pone.0041865","volume":"7","author":"Seidah N.G.","year":"2012","unstructured":"Seidah N.G.; Poirier S.; Denis M.; Parker R.; Miao B.; Mapelli C.; Prat A.; Wassef H.; Davignon J.; Hajjar K.A.; Mayer G.; Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One 2012,7(7),e41865","journal-title":"PLoS One"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"Ray K.K.","year":"2017","unstructured":"Ray K.K.; Landmesser U.; Leiter L.A.; Kallend D.; Dufour R.; Karakas M.; Inclisiran in patients with high CV risk and elevated LDL-cholesterol. N Engl J Med 2017,376,1430-1440","journal-title":"N Engl J Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.chembiol.2013.11.014","volume":"21","author":"Schroeder C.I.","year":"2014","unstructured":"Schroeder C.I.; Swedberg J.E.; Withka J.M.; Rosengren K.J.; Akcan M.; Clayton D.J.; Daly N.L.; Cheneval O.; Borzilleri K.A.; Griffor M.; Stock I.; Colless B.; Walsh P.; Sunderland P.; Reyes A.; Dullea R.; Ammirati M.; Liu S.; McClure K.F.; Tu M.; Bhattacharya S.K.; Liras S.; Price D.A.; Craik D.J.; Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro. Chem Biol 2014,21(2),284-294","journal-title":"Chem Biol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"10561","DOI":"10.1074\/jbc.M808802200","volume":"284","author":"McNutt M.C.","year":"2009","unstructured":"McNutt M.C.; Kwon H.J.; Chen C.; Chen J.R.; Horton J.D.; Lagace T.A.; Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 2009,284(16),10561-10570","journal-title":"J Biol Chem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1074\/jbc.M113.514067","volume":"289","author":"Zhang Y.","year":"2014","unstructured":"Zhang Y.; Eigenbrot C.; Zhou L.; Shia S.; Li W.; Quan C.; Tom J.; Moran P.; Di Lello P.; Skelton N.J.; Kong-Beltran M.; Peterson A.; Kirchhofer D.; Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem 2014,289(2),942-955","journal-title":"J Biol Chem"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"43054","DOI":"10.1074\/jbc.M111.273474","volume":"286","author":"Du F.","year":"2011","unstructured":"Du F.; Hui Y.; Zhang M.; Linton M.F.; Fazio S.; Fan D.; Novel domain interaction regulates secretion of proprotein convertase subtilisin\/kexin type 9 (PCSK9) protein. J Biol Chem 2011,286(50),43054-43061","journal-title":"J Biol Chem"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ejmech.2007.02.015","volume":"42","author":"da Costa Leite L.F.C.","year":"2007","unstructured":"da Costa Leite L.F.C.; Veras Mour\u00e3o R.H.; de Lima Mdo.C.; Galdino S.L.; Hernandes M.Z.; de Assis Rocha Neves F.; Vidal S.; Barbe J.; da Rocha Pitta I.; Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. Eur J Med Chem 2007,42(10),1263-1271","journal-title":"Eur J Med Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211027125245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197430\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867328666211027125245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T03:15:41Z","timestamp":1673666141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197430\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":157,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867328666211027125245","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}